AbCellera Biologics (ABCL) Stock Forecast & Price Target

AbCellera Biologics is supported by a diversified antibody discovery platform that targets high-value, hard-to-drug biology, with two clinical candidates, two IND/CTA-enabling programs, and more than 20 active discovery efforts across multiple modalities. Recent catalysts strengthen the outlook: ABCL635 Phase 2 data in moderate-to-severe VMS are expected very soon, and if efficacy and safety outperform existing therapies, the program could address a growing market already showing ~$94M quarterly sales for Veozah, up 53% year over year. Financially, the company also appears well positioned, with $565M in cash and marketable securities as of 2Q26 plus new collaboration economics from Jazz and Vertex that should support revenues, earnings, and operating cash through fiscal 2027E.

AbCellera Biologics is viewed negatively because its lead programs remain in early-stage development, leaving substantial clinical uncertainty around safety, efficacy, and eventual regulatory success. The company’s therapeutic rationale and early proof-of-concept data may not translate in later trials, which is especially problematic for a clinical-stage biotechnology business with a pipeline still concentrated in discovery and IND/CTA-enabling work rather than proven late-stage assets. With only two drug candidates in clinical development and the rest still advancing through early programs, the fundamental risk profile remains high and the path to durable value creation remains unproven.